07:47 AM EDT, 10/06/2025 (MT Newswires) -- Skye Bioscience ( SKYE ) shares plummeted more than 58% in recent premarket activity after it said Monday that its phase 2a trial of nimacimab to treat patients with obesity missed its primary endpoint of weight loss compared with placebo.

The company said its preliminary analysis found that the 200 mg, subcutaneous weekly dose "was suboptimal as a monotherapy."

Skye Bioscience ( SKYE ) said it will host a conference call and webcast to discuss the results at 8 am ET.

Price: 1.98, Change: -2.77, Percent Change: -58.32